Skip to main content
. 2012 Aug 3;97(10):3584–3592. doi: 10.1210/jc.2012-2393

Table 1.

Participant and disease characteristics at enrollment (n = 50)

Value at enrollment
Age [median (range) yr] 7.9 (5.1–22.1)
Sex, male [n (%)] 19 (38)
Race, Black [n (%)] 5 (10)
Tanner stage [n (%)]
    Prepubertal (Tanner 1) 32 (64)
    Pubertal (Tanner 2–3) 7 (14)
    Postpubertal (Tanner 4–5) 11 (22)
Age at leukemia diagnosis [median (range) yr] 4.9 (1.4–19.7)
Duration of therapy [median (range) yr] 2.3 (1.3–3.4)
Time since completion of therapy [median (range) yr] 0.8 (0.0–2.2)
Diagnosis [n (%)]
    Precursor B ALL 49 (98)
    T-cell ALL 1 (2)
Leukemia risk [n (%)]
    Standard 33 (66)
    High 17 (34)
Cumulative Steroids [n (%), median (range)]
    Dexamethasone (g/m2) 49 (98), 1.1 (0.1–1.6)
    Prednisone (g/m2) 15 (30), 4.3 (0.5–6.8)
Nonphalangeal fractures (n) (10 fractures; 9 patients)
    At leukemia diagnosis 2
    During leukemia treatment 7
    After leukemia treatment 1
Laboratory parameters [median (range)]
    Calcium (mg/dl) 9.4 (8.9–10.2)
    Intact PTH (pg/ml) 29 (3–66)
    25(OH)D (ng/ml) 30.9 (4.1–93.6)